CSF3 and graft versus host disease: demonstrated that LD-PTCy can enhance the preventive effect of G-CSF/ATG on GVHD, and reduced incidences of aGVHD and cGVHD without compromising graft function and anti-tumor effect have been prospectively confirmed in a group of patients with high GVHD risk (21).